A recent uncontrolled, phase 1–2a study in Japan suggested the use of mogamulizumab (an anti-CCR4 monoclonal antibody) decreased the number of HTLV-1-infected cells and the levels of inflammatory markers in HAM/TSP patients (Sato et al., 2018). The gene discussed is CCR4; the disease is tropical spastic paraparesis.